No time dependence of ciprofloxacin pharmacokinetics in critically ill adults: Comparison of individual and population analyses

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10429901" target="_blank" >RIV/00216208:11110/21:10429901 - isvavai.cz</a>

Alternative codes found

RIV/60461373:22330/21:43922257 RIV/00064203:_____/21:10429901 RIV/00216208:11130/21:10429901

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=lLSWk45DuY" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=lLSWk45DuY</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/pharmaceutics13081156" target="_blank" >10.3390/pharmaceutics13081156</a>

Result language

angličtina

Original language name

No time dependence of ciprofloxacin pharmacokinetics in critically ill adults: Comparison of individual and population analyses

Original language description

The aim of this prospective PK study was to evaluate the pharmacokinetics of ciprofloxacin dosed within the first 36 h (early phase) and after 3 days of treatment (delayed phase) using individual and population PK analysis. The secondary aim of the study was to evaluate possible dosing implications of the observed PK differences between early and delayed phases to achieve a PK/PD target for ciprofloxacin of AUC24/MIC &gt;= 125. Blood concentrations of ciprofloxacin (1 and 4 h after dose and trough) were monitored in critically ill adults in the early and delayed phases of the treatment. Individual and population PK analyses were performed. Complete concentrationtime profiles in the early phase, delayed phase, and both phases were obtained from 29, 15, and 14 patients, respectively. No systematic changes in ciprofloxacin PK parameters between the early and delayed phases were observed, although variability was higher at the early phase. Both individual and population analyses provided similar results. Simulations showed that after standard dosing, it is practically impossible to reach the recommended ciprofloxacin PK/PD target (AUC/MIC &gt;= 125) for pathogens with MIC &gt;= 0.5 mg/L. A dosing nomogram utilizing patients&apos; creatinine clearance and MIC values was constructed. Both individual and population analyses provided similar results. Therapeutic drug monitoring should be implemented to safeguard the optimal ciprofloxacin exposure.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

<a href="/en/project/LTAUSA19049" target="_blank" >LTAUSA19049: Endogenous biomarkers of ciprofloxacin induced neurological adverse drug reactions</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pharmaceutics [online]

ISSN

1999-4923

e-ISSN

—

Volume of the periodical

13

Issue of the periodical within the volume

8

Country of publishing house

CH - SWITZERLAND

Number of pages

14

Pages from-to

1156

UT code for WoS article

000690157400001

EID of the result in the Scopus database

2-s2.0-85111733765